Assembly Biosciences Reports Positive Phase 1b Trial Results for ABI-5366 and ABI-1179 in Recurrent Genital Herpes

Assembly Biosciences presented findings from Phase 1b clinical trials for two investigational therapies, ABI-5366 and ABI-1179, at the ESCMID Global Conference in 2026. The studies focused on evaluating the safety, tolerability, and antiviral activity of these treatments in patients with recurrent genital herpes. Researchers shared data indicating positive outcomes from both trials.

The Phase 1b trial for ABI-5366 assessed its ability to reduce viral shedding and improve symptoms associated with recurrent genital herpes. Results showed favorable safety profiles and promising antiviral effects in participants. Similarly, the study of ABI-1179 demonstrated encouraging results regarding its efficacy and tolerability. Both presentations highlighted advancements in therapeutic approaches aimed at addressing unmet needs in managing recurrent genital herpes infections.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 9, 2026

Author

GOAI